Table 1 Demographic characteristics of IMPROVE and UKB participants.

From: The overlap of genetic susceptibility to schizophrenia and cardiometabolic disease can be used to identify metabolically different groups of individuals

 

IMPROVE

UKB1

UKB2

Nmax

3300

2202

20,182

Male (%)

1695 (51.4)

1042 (47.3)

9759 (48.4)

Baseline

Age (years)

64.2 (5.4)

55.7 (7.6)

55.2 (7.5)

Weight (kg)

76.7 (15.1)

76.1 (14.5)

76.9 (14.8)

Waist (cm)

94 (13)

88 (12)

88 (13)

Hip (cm)

102 (10)

102 (8)

102 (8)

WHR

0.92 (0.09)

0.86 (0.09)

0.86 (0.09)

BMI (kg/m2)

27.3 (4.2)

26.4 (3.9)

26.6 (4.2)

SBP (mmHg)

142 (18)

136 (18)

136 (18)

DBP (mmHg)

82 (10)

82 (10)

82 (10)

SBP* (mmHg)

151 (21)

138 (19)

138 (19)

DBP* (mmHg)

88 (11)

83 (11)

83 (11)

T2D

880 (26.7)

46 (2.1)

45 (2.2)

HTN

2634 (79.8)

974 (45.0)

8765 (45.2)

HTN medication

1904 (57.7)

332 (15.2)

2820 (14.0)

Lipid-lowering medication

1623 (49.2)

172 (18.4)

1677 (18.9)

ISH

0 (0)

21 (1.0)

259 (1.3)

IMTmean (mm)

0.891 (0.199)

na

na

IMTmax (mm)

2.037 (0.813)

na

na

Current smoking

498 (15.1)

139 (6.3)

1234 (6.1)

Former smoking

1216 (36.9)

746 (33.9)

6656 (33.0)

Follow-up

Age

66.7 (5.4)

61.8 (7.5)

63.2 (7.5)

Weight

na

75.6 (14.6)

76.3 (15.0)

Waist

na

86 (12)

88 (12)

Hip

na

100 (8)

101 (9)

WHR

na

0.86 (0.08)

0.87 (0.09)

BMI

na

26.4 (4.0)

26.5 (4.4)

SBP

na

138 (20)

137 (18)

DBP

na

83 (11)

79 (10)

SBP*

na

140 (20)

141 (20)

DBP*

na

81 (11)

81 (11)

T2D

na

79 (3.6)

867 (4.3)

HTN

na

1121 (51.5)

12,414 (62.0)

HTN medication

na

466 (21.2)

4568 (22.7)

Lipid-lowering medication

na

408 (22.3)

4557 (26.4)

ISH

119 (3.6)

43 (2.0)

333 (1.7)

IMTmean (mm)

na

0.672 (0.119)

0.682 (0.125)

IMTmax (mm)

na

0.888 (0.182)

0.914 (0.297)

Progression of IMTmean

0.0186 (0.032)

na

na

Progression of IMTmax

0.0439 (0.163)

na

na

Current smoking

na

99 (4.6)

708 (3.5)

Former smoker

na

742 (34.1)

6800 (33.9)

MHQ

Nmax (% of group)

na

1528 (69.4)

10,079 (49.9)

BD

na

28 (1.8)

196 (1.4)

MDD

na

410 (29.9)

3512 (28.6)

  1. Where: *, adjusted to provide estimates of treatment-naïve levels, as per Ehret etl al; na, not available.